RSV Vaccine Effectiveness Drops Among Older Adults: Study

Respiratory syncytial virus vaccination initially provided strong protection, researchers found.

A colorized scanning electron micrograph shows human respiratory syncytial virus (RSV) virions shedding from human lung epithelial cells. NIAID via The Epoch Times

Vaccines against respiratory syncytial virus (RSV) initially provided strong protection, but that shielding dropped over time, researchers said in a new paper.

Among adults aged at least 60, a vaccine provided 71 percent protection against RSV infection at four months, Kersten Bartlet and other researchers said in a paper published on Aug. 19 by Epic Systems Corporation. The shielding dropped to 40 percent by month 19.